Fertility sparing surgery (FSS) in patients with malignant ovarian tumors

Malignant ovarian tumors, for young women in the reproductive age group who desire preservation of fertility, is still one of the most difficult diseases for diagnosing and treatment in onco-gynecological surgery. It becomes first one in discussion about controversies in medical treatment and diagnostical standards.
In the article authors, basing on current literature data and theirs own experiences, present review of fertility sparing operations in patients with malignant ovarian tumors.
Patients with germ cell tumours (the most common ovarian tumours in young women) and borderline tumors are best candidates to fertility-sparing surgery. Additionally development created by modern chemotherapy based on platin and taxoids, caused obvious therapeutical benefit helping avoid reccurence of the disease. It solved lots of therapeutical problems in young women treated with fertility sparing surgery.
We suggest that patients of stage I who wish to preserve childbearing function may be treated with unilateral salpingo-ovariectomy and depending on histopathological type- chemotherapy. The type of the primary operation depends on age, parity, stage and histological type of ovarian tumors. The operative treatment should be so conservative as possible employing all diagnostic and monitoring methods. And the careful diagnosis before the operation reduces the risk of qualifying patients with malignant changes to FSS.
As we show in the article, the management of MOGCTs (malignant ovarian germ cell tumors), borderline tumors and other tumors in early stadiums with fertility-sparing surgery is a safe, practicable treatment option.
The majority of these patients can retain normal ovarian function and reproductive potential after fertility sparing treatment.